Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
07 März 2022 - 05:47PM
Edgar (US Regulatory)
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2022
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
7
March 2022 15:30 GMT
Transactions by Persons Discharging Managerial
Responsibilities
AstraZeneca
PLC (the Company) announced that, on 4 March 2022, certain Persons
Discharging Managerial Responsibilities of the Company (PDMRs) were
granted awards of the Company's ordinary shares of $0.25 each
(Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus
Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as
detailed in the table below.
|
PDMR
|
Ordinary Shares granted under the AZDBP
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
|
Pascal
Soriot
|
17,216
|
97,066
|
£91.54
|
|
Aradhana
Sarin
|
3,249
|
43,038
|
£91.54
|
The
AZDBP award represents the portion of each PDMR's annual bonus for
2021 that they are required to defer into shares. The Ordinary
Shares granted under the AZDBP are subject to a three-year holding
period and are due to vest on the third anniversary of
grant.
The
AZPSP award is subject to a combination of performance measures
focused on scientific, ESG, commercial, and financial performance.
The performance measures will be assessed over a three-year
performance period (1 January 2022 to 31 December 2024). The
Ordinary Shares granted under the AZPSP are subject to a two-year
holding period following the performance period, and are due to
vest on the fifth anniversary of grant.
Details of the performance measures attached to
the AZPSP award can be found in the Directors' Remuneration Report
within the AstraZeneca Annual Report and Form 20-F Information
2021, which is available on the Company's website
at www.astrazeneca.com/annualreport2021.
Further
details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Pascal
Soriot
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief
Executive Officer
|
|
b)
|
Initial
notification /Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca
PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
Identification
code
|
Ordinary
Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature
of the transaction
|
Grants
of share awards under the AstraZeneca Performance Share Plan and
the AstraZeneca Deferred Bonus Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£91.54
|
114,282
|
|
d)
|
Aggregated
information
-
Aggregated volume
-
Price
|
Not
applicable - single transaction
|
|
e)
|
Date
of the transaction
|
4
March 2022
|
|
f)
|
Place
of the transaction
|
Outside
a trading venue
|
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Aradhana
Sarin
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief
Financial Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca
PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
Identification
code
|
Ordinary
Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature
of the transaction
|
Grants
of share awards under the AstraZeneca Performance Share Plan and
the AstraZeneca Deferred Bonus Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£91.54
|
46,287
|
|
d)
|
Aggregated
information
-
Aggregated volume
-
Price
|
Not
applicable - single transaction
|
|
e)
|
Date
of the transaction
|
4
March 2022
|
|
f)
|
Place
of the transaction
|
Outside
a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor
Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
07 March 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mai 2022 bis Jun 2022
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jun 2021 bis Jun 2022
